shares glaxo holdings plc fell following report today new england journal medicine antibiotics may able treat ulcers threatening glaxo billion dlr antiulcer drug zantac analysts said glaxo was trading off volume 786 800 shares shares smithkline beckman maker popular anti ulcer drug tagamet also fell anything raises possiblity entirely new therapy for ulcers would attack core glaxo worldwide business which zantac said david maccallum analyst follows glaxo for hambrecht and quist zantac world most prescribed drug with annual sales over billion dollars accounting for almost pct glaxo earnings said maccallum any perception zantac not therapy choice for ulcers glaxo sales and profits could decline said tina rizopuolos analyst with alexanders laing and kshnk rizopuolos said new england journal article led university toronto researcher concludes from study children with gastric disease bacteria could gastritis and ulcers editorial same issue medical journal richard hornick university rochester school medicine reviewed studies using antibiotics treat ulcers rizopuolos said hornick concludes bacteria ulcer relationship exciting and intriguing but further studies needed direct causal effect ulcers when stomach protective lining erodes and exposed underlying inflamed tissue but unknown actually causes process known stomach acids exacerbate ulcers and therefore antacids were commonly used alleviate ulcers before tagamet and zantac came along both these drugs prevent release hormone histamine stomach which triggers acid secretion think people should run out and sell glaxo said analyst rizopuolos will long time displace tagamet and zantac those drugs going prescribed physicians for long time added reuter 